Trial · NCT02847598
Results by group758
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 758
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 | Part A: Placebo | -12.7 | Standard Deviation 10.3 | joints | |
| Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 | Part A: BIIB059 50 mg | -9.0 | Standard Deviation 5.7 | joints | |
| Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 | Part A: BIIB059 150 mg | -13.0 | Standard Deviation NA | joints | |
| Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 | Part A: BIIB059 450 mg | -14.5 | Standard Deviation 8.7 | joints | |
| Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16 | Part B: Placebo | -15.03 | Standard Deviation 37.23 | percent change | |
| Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16 | Part B: BIIB059 50 mg | -35.52 | Standard Deviation 33.35 | percent change | |
| Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16 | Part B: BIIB059 150 mg | -47.11 | Standard Deviation 34.10 | percent change | |
| Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16 | Part B: BIIB059 450 mg | -41.66 | Standard Deviation 37.33 | percent change | |
| Part A : Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 24 | Part A: Placebo | 42.11 | percentage of participants | ||
| Part A : Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 24 | Part A: BIIB059 50 mg | 50 | percentage of participants | ||
| Part A : Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 24 | Part A: BIIB059 150 mg | 16.67 | percentage of participants | ||
| Part A : Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 24 | Part A: BIIB059 450 mg | 64.10 | percentage of participants | ||
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: Placebo | Week 12 | 12.12 | percentage of participants | |
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: BIIB059 50 mg | Week 12 | 38.46 | percentage of participants | |
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: BIIB059 150 mg | Week 12 | 48.00 | percentage of participants | |
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: BIIB059 450 mg | Week 12 | 37.50 | percentage of participants | |
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: Placebo | Week 16 | 21.88 | percentage of participants | |
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: BIIB059 50 mg | Week 16 | 38.46 | percentage of participants | |
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: BIIB059 150 mg | Week 16 | 44.00 | percentage of participants | |
| Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16 | Part B: BIIB059 450 mg | Week 16 | 46.51 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02847598/results